Claudia Lin, Ph.D. has been named general manager of Alphamab (Jiangsu) Biopharmaceuticals Co., Ltd., a newly established subsidiary to manufacture and develop multiple novel biologics in the Alphamab pipeline. Additionally, Mike Liu, Ph.D., was appointed executive vice president to lead global business development.
 
Dr. Lin previously served as vice president at Innovent Biologics, responsible for GMP compliance and Quality management. Prior to Innovent, Dr. Lin served as head of Quality Assurance for Bayer Healthcare Biotech division, responsible for all products in clinical development stages through to initial product launch. She also held various Quality leadership positions in Genentech/Roche.
 
Dr. Liu previously served as head of global business development at Hengrui Pharmaceuticals, where he closed dozens of licensing and partnership agreements with leading multi-national and Chinese companies. Previously, Dr. Liu held positions of increasing responsibility for global commercial development at Alexion Pharmaceuticals and licensing & business development at Purdue Pharma.
 
“We are delighted to have Dr. Lin and Dr. Liu join us,” said Dr. Ting Xu, chairman and chief executive officer of Alphamab. “They are bringing in very valuable expertise and experience in biologics quality management, manufacturing, and business development. As Alphamab grows rapidly, their addition will enable us to expand our global footprint.”